Moxifloxacin for the treatment of pulmonary tuberculosis in children: A single center experience

Pediatric Pulmonology

Volumn 49, Issue 4, 2014, Pages 372-376

  Garazzino, Silvia ^a   Scolfaro, Carlo ^a   Raffaldi, Irene ^a   Barbui, Anna Maria ^a   Luccoli, Luigi ^b   Tovo, Pier Angelo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

multidrug resistant mycobacteria; pediatrics; quinolones

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADOLESCENT; ANKLE ARTHRITIS; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM CULTURE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD DISEASE; CHILL; CLINICAL ARTICLE; DRUG FEVER; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HUMAN; HYPOTENSION; INFANT; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; QT PROLONGATION; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; PROSPECTIVE STUDY; TUBERCULOSIS, PULMONARY;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FLUOROQUINOLONES; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 84896399768     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22755     Document Type: Article

References (28)

1. Alghasham AA, Nahata MC,. Clinical use of fluoroquinolones in children. Ann Pharmacother 2000; 34: 347-359.
2. Centers for Diseases Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs: worldwide, 2000-2004. MMWR 2006; 55: 301-305. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5511a2.htm. Accessed April 20, 2012.
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva, Switzerland: World Health Organization; 2008. WHO/HTM/TB/2008.402. Available at: http://whqlibdoc.who.int/publications/2008/9789241547581-eng.pdf. Accessed April 20, 2012.
4. Istituto Superiore di Sanità. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute. Tubercolosi. Available at: htpp://www.epicentro.iss.it/problemi/Tubercolosi/Tb-Mdr-Xdr.asp Accessed April 20, 2012.
5. Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T,. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 2010; 65: 946-952.
6. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B,., Mitchison DA,. Gatifloxacin for TB (OFLOTUB) study team. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138.
7. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F,. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67: 2077-2099.
8. Ziganshina LE, Squire SB,. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008; 23: 1-58.
9. Schaaf HS, Marais BJ,. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011; 12: 31-38.
10. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva, Switzerland: World Health Organization; 2006. WHO/HTM/TB/2006.371. Available at: http://whqlibdoc.who. int/hq/2006/WHO-HTM-TB-2006.371-eng.pdf. Accessed April 20, 2012.
11. World Health Organization. Rapid advice. Treatment of tuberculosis in children. Geneva, Switzerland: World Health Organization; 2010. WHO/HTM/TB/2010.13. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241500449-eng.pdf. Accessed April 20, 2012.
12. Seddon JA, Hesseling AC, Marais BJ, McIlleron H, Peloquin CA, Donald PR, Schaaf HS,. Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis 2012; 92: 9-17.
13. Perez-Velez C,. Pediatric tuberculosis: new guidelines and recommendations. Curr Op Pediatr 2012; 24: 319-328.
14. Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE,. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
15. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R,. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-612.
16. Ingham B, Brentnall D, Dale E, McFadzean J,. Arthropathy induced by antibacterial fused N-Alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977; 1: 21-26.
17. Burkhardt JE, Walterspiel JN, Schaad UB,. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25: 1196-1204.
18. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 2006; 118: 1287-1292.
19. Leibovitz E,. The use of fluoroquinolones in children. Curr Opin Pediatr 2006; 18: 64-70.
20. Chauny JV, Lorrot M, Prot-Labarthe S, De Lauzanne A, Doit C, Géréral T, Bourdon O,. Treatment of tuberculosis with levofloxacin or moxifloxacin: report of six pediatric cases. Pediatr Infect Dis J 2012; 31: 1309-1311.
21. Pinon M, Scolfaro C, Bignamini E, Cordola G, Esposito E, Milano R, Mignone F, Bertaina C, Tovo PA,. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics 2010; 126: e1253-e1256.
22. Chiang C-Y, Schaaf HS,. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 672-682.
23. Al-Dabbagh M, Lapphra K, McGloin R, Inrig K, Schaaf HS, Marais BJ, Sauve L, Kitai I, Kollmann TR,. Drug-resistant tuberculosis. Pediatric guidelines. Pediatr Infect Dis J 2011; 30: 501-505.
24. Rastogi N, Goh KS, Bryskier A, Devallois A,. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 1610-1616.
25. Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh TD,. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 2005; 56: 1169-1171.
26. Clinicaltrials, gov. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMoxTB). March 2009. Available at: http://clinicaltrials.gov/ct2/show/NCT00864383?term= moxifloxacin&rank=1. Accessed April 20, 2012.
27. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB,. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
28. Torres JR, Bajares A,. Severe acute polyarthritis in a child after high doses of moxifloxacin. Scand J Infect Dis 2008; 40: 582-584.